IN8bio preclinical data shows DeltEx gamma-delta T cells kill ovarian cancer cells, including resistant lines

IN8BIO, INC.

Data presented at ASGCT 2023 demonstrate DeltEx T cells target and kill ovarian cancer cells even in platinum-resistant lines.
Temozolomide (TMZ) combined with PARP inhibitors synergistically increased NKG2D-L expression, enhancing tumor cell visibility to gamma-delta T cells.
CEO William Ho highlighted synergy of gamma-delta T cells with chemotherapy for solid tumors beyond the brain.
CSO Lawrence Lamb noted potential for INB-400 in ovarian cancer and other solid tumors; further evaluation planned.
Preclinical proof-of-concept supports DeltEx Drug Resistance Immunotherapy (DeltEx DRI) platform in challenging indications.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.